Cutaneous T cell Lymphoma Pipeline Analysis Report 2026

Cutaneous T-cell lymphomas (CTCL) are rare, skin-predominant non-Hodgkin lymphomas characterized by malignant T-cell infiltration of the skin, with mycosis fungoides representing the most common subtype. As reported by recent European epidemiological evidence (2025), CTCL has an incidence of approximately 0.3 cases per 100,000 patient-years across Europe. According to the cutaneous T-cell lymphoma pipeline analysis, the therapeutic pipeline is steadily expanding, driven by persistent unmet clinical needs and advances in immunology and targeted drug development. Emerging treatment approaches include monoclonal antibodies, antibody-drug conjugates, immune modulators, and novel targeted therapies.

Report Coverage

The Cutaneous T-cell Lymphoma Pipeline Analysis Report gives comprehensive insights into cutaneous T-cell lymphoma (CTCL) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for cutaneous T-cell lymphoma (CTCL). The cutaneous T-cell lymphoma (CTCL) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The cutaneous T-cell lymphoma (CTCL) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with cutaneous T-cell lymphoma (CTCL) treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to cutaneous T-cell lymphoma (CTCL).

Cutaneous T cell Lymphoma Pipeline Outlook

CTCL is a rare non-Hodgkin lymphoma caused by malignant T-cell proliferation leading to skin-homing lymphocyte infiltration, cytokine dysregulation, and tumor microenvironment immune escape. Disease progression is associated with chronic inflammation, immune evasion pathways, and genetic mutations affecting T-cell signaling. Current treatment strategies include skin-directed therapy, systemic immunotherapy, immune checkpoint inhibitors, targeted biologics, and emerging cell-based therapies, aiming to improve lesion clearance, reduce pruritus, and enhance survival outcomes. Denileukin diftitox-cxdl (Lymphir) is a recombinant fusion protein targeting interleukin-2 receptors on malignant T-cells, approved by the FDA in August 2024 for relapsed or refractory Cutaneous T-cell Lymphoma. It demonstrated a 36.2% objective response rate in Phase 3 trials, offering a novel targeted systemic treatment option.

Cutaneous T cell Lymphoma Epidemiology

According to Soligenix, cutaneous T-cell lymphoma (CTCL) is a rare subset of non-hodgkin lymphoma, accounting for nearly 4% of over 1.7 million cases in the United States and Europe. It affects approximately 31,000 individuals in the United States with nearly 3,200 new cases annually, and around 38,000 individuals in Europe with about 3,800 new cases annually, based on SEER and ECIS data. As per Chalid Assaf et al., 2023, incidence ranged from 3.65 to 3.92 per 100,000, with a six-year prevalence of 27.35-43.58 per 100,000. The patient population was predominantly male, highlighting a steady disease burden.

Cutaneous T cell Lymphoma - Pipeline Therapeutic Assessment

This section of the report covers the analysis of cutaneous T cell lymphoma drug candidates based on several segmentations including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The cutaneous T cell lymphoma pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Gene Therapies
• Peptides
• Polymers

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Cutaneous T cell Lymphoma Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 47%, covers a major share of the total cutaneous T cell lymphoma clinical trials. It is followed by phase I at 46% and phase III at 4%. This strong mid-stage concentration indicates robust clinical progression, supporting accelerated development, improved therapeutic options, and positive market expansion through innovation and late-stage validation.

Cutaneous T cell Lymphoma Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the cutaneous T cell lymphoma pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The cutaneous T cell lymphoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for cutaneous T cell lymphoma. Targeted therapies, including monoclonal antibodies and kinase inhibitors, are emerging as key drug class segments. For instance, lacutamab, a first-in-class anti-KIR3DL2 monoclonal antibody, is being evaluated in Phase 3 TELLOMAK 3 trials for Sézary syndrome and mycosis fungoides. Moreover, novel biologics aims to improve response rates and address high unmet clinical needs in relapsed and refractory cutaneous T-cell lymphoma patients.

Cutaneous T cell Lymphoma Clinical Trials - Key Players

The report for the cutaneous T cell lymphoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed cutaneous T cell lymphoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in cutaneous T cell lymphoma clinical trials:

• Soligenix
• Domain Therapeutics SA
• Boston Immune Technologies and Therapeutics
• Legend Biotech USA Inc.
• SciTech Development, Inc.
• Jiangsu Simcere Biologics Co., Ltd
• Kyowa Kirin, Inc.
• Treeline Biosciences, Inc.
• Bio-Path Holdings, Inc.
• Daiichi Sankyo Co., Ltd.
• Seagen Inc.
• Bristol Myers Squibb Company

Cutaneous T cell Lymphoma - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for cutaneous T cell lymphoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of cutaneous T cell lymphoma drug candidates.

Drug: Hypericin

HyBryte™ (Hypericin Sodium Gel) is a topical photosensitizing drug being administered by Soligenix in a Phase 3 confirmatory study for cutaneous T-cell lymphoma (CTCL). The study examines whether twice-weekly application of 0.25% hypericin gel, followed by visible-light activation, induces lesion reduction in patch/plaque mycosis fungoides patients. The drug functions as a photoactive agent generating cytotoxic reactive oxygen species upon light exposure, targeting malignant T-cells locally. The trial is being sponsored by Soligenix and is evaluating efficacy and safety over 18 weeks, with estimated completion in October 2026. It is being applied topically and assessed against a placebo under double-blind conditions.

Biological: BITR2101

BITR2101 is a monoclonal antibody therapy sponsored by Boston Immune Technologies and Therapeutics, which is being administered through intravenous infusion every three weeks in a Phase 1, first-in-human, dose-escalation study. The drug functions by targeting and inhibiting Tumor Necrosis Factor Receptor 2 (TNFR2), a key signaling molecule that supports lymphoma cell survival, proliferation, and immune evasion in cutaneous T cell lymphoma. The study examines safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in relapsed or refractory non-hodgkin lymphoma patients. It is currently not yet recruiting and is expected to be completed by February 2027.

Drug: DT-7012

DT-7012, a Domain Therapeutics anti-CCR8 monoclonal antibody, is being developed as an intravenous immunotherapy for relapsed or refractory cutaneous T-cell lymphomas, including mycosis fungoides and Sézary syndrome. Sponsored by Assistance Publique-Hôpitaux de Paris, this Phase 1 first-in-human, multicenter, open-label, dose-escalation study is examining safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy. The drug is targeting CCR8-expressing regulatory T cells and is mediating tumor cell depletion through ADCC and ADCP, thereby reshaping the tumor microenvironment. Study completion is expected in August 2028 and is ongoing.

Key Questions Answered in the Cutaneous T cell Lymphoma Pipeline Insight Report

• Which companies/institutions are leading cutaneous T cell lymphoma drug development?
• Which company is leading the cutaneous T cell lymphoma pipeline development activities?
• What is the current cutaneous T cell lymphoma commercial assessment?
• What are the opportunities and challenges present in the cutaneous T cell lymphoma pipeline landscape?
• What is the efficacy and safety profile of cutaneous T cell lymphoma pipeline drugs?
• Which company is conducting major trials for cutaneous T cell lymphoma drugs?
• Which companies/institutions are involved in cutaneous T cell lymphoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in cutaneous T cell lymphoma?

Reasons To Buy This Report

The Cutaneous T cell Lymphoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for cutaneous T cell lymphoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into cutaneous T cell lymphoma collaborations, regulatory environments, and potential growth opportunities.